Formycon has claimed the first Keytruda biosimilar filing with the US FDA, with the Zydus-partnered pembrolizumab product also set to provide an early test of the US agency’s new streamlined approach to biosimilar evaluation.
Formycon has claimed the first Keytruda biosimilar filing with the US FDA, with the Zydus-partnered pembrolizumab product also set to provide an early test of the US agency’s new streamlined approach to biosimilar evaluation.